At the beginning of 2021, the representatives of the Republic of Belarus inspected Farmak’s manufacturing, warehouse, laboratory facilities and the functioning of its pharmaceutical quality system. Following the inspection, the Company’s facilities engaged in manufacturing of finished medicinal products have got the EAEU GMP Certificate.
The EAEU GMP Certificate becomes a prerequisite for the registration/re-registration and sale of medicinal products in the markets of the EAEU member states (Belarus, Kazakhstan, Kyrgyzstan, etc.) and will reduce the number of inspections carried out by local regulatory authorities of the EAEU member states.
“The key thing for us is to provide consumers with high-quality innovative medicines. To achieve this, we strictly adhere to all international standards and requirements for the manufacture of medicinal products. This is clearly confirmed by the certification following world inspections which Farmak passes every year. We are now preparing for the FDA* compliance inspection to enter the U.S. market,” said Volodymyr Kostiuk, Chief Executive Officer of Farmak.
Today, Farmak’s facilities engaged in manufacturing of finished medicinal products have not only the national GMP certificate, but are also certified by the European regulatory authorities. This makes it possible to sell products in markets with particularly stringent requirements for the quality and safety of medicinal products.
Besides, last year, Dexamethasoni Phosphas with dexamethasone as an active substance was successfully prequalified by the World Health Organization and is listed among the medicinal products with proven quality and efficacy in 2 groups: HIV/AIDS and COVID-19.
At year-end 2020, Farmak increased its exports by 40%, having shipped products to more than 30 countries in the EU, Central and South America, the CIS, the Middle East, Asia, etc. Today, the share of exports in the Company’s total sales is 29.6%.
*U.S. Food and Drug Administration
Farmak, the Ukrainian pharmaceutical market leader, is implementing the project entitled “Electronic batch dossier of a medicinal product” which will fully replace the hard-copy information carriers on a medicinal product batch manufacturing with electronic ones. Siemens, which introduced similar systems for global pharmaceutical giants Bayer, Johnson&Jo...
Whether the refined processes can promote developing medicinal products? Yes, as far as the new innovative centre of Farmak as the Ukrainian pharmaceutical market leader is concerned. The Company intends to improve its operations as much as possible, provide personnel with comfortable office space, but most importantly to expand the capabilities of its R&...
Pharmaceutical company Farmak’s operational efficiency growth strategy is based on the culture of continuous improvement and Lean Manufacturing. Following the successful implementation of the Lean pilot project, the Company is introducing this concept throughout its manufacturing facilities and in logistics processes. Lean OREX-2025 pilot project was launche...